Practical 9 - Cardiovascular Risk Assessment Flashcards
who should be assessed for CVD risk
men 45 years and older
women 55 years and older
in maori, pacific or south asain populations assessment should begin
15 years earlier
if there is a first degree relative with : diabetes, heart attack prior to 50 y, familial hypercholesteroliemia then CVD risk assessment should be initiated when
10 years earlier
in individuals who smoke, have a history of gestational diabetes, have pre diabetes, have BMI>30, have atrial fibrillation then CVD risk assessment should be initiated when
10 years earlier
the equations have not been developed to calculate risk in people who :
- have pre existing CVD
- have chronic heart failure, familial hypercholesterolemia, chronic kidney disease or diabetes with overt renal disease
- people over 75 years of age
CVD risk assessment in people with severe mental illness should be initiated when
at 25 years of age
there are seperate CVD risk equations for who
men and women and people with and without diabetes
diabetes specific equations for CVD risk also include
- years since diagnosis
- eGFR
- HbA1c
- oral hypoglycaemic medication
- on insulin
what is included in CVD risk equations
- age
- ethnicity
- smoking status
- family history of premature CVD
- atrial fibrillation
- systolic blood pressure
- BMI
- total cholesterol to HDL cholesterol ratio
- BP lowering medication
- lipid lowering medication
- antiplatelet or anticoagulant medications
when there is a <5% CVD risk what is the drug therapy advice
evidence indicates medication management has limited benefit
when there is a 5-15% CVD risk what is the drug therapy advice
discuss the magnitude of benefits, based on the evidence that the higher the risk for the patient, the more likely they are to benefit
when there is a >15% CVD risk what is the drug therapy advice
strong evidence supports using statins and blood pressure lowering to prevent CVD events and deaths
when there is established CVD what is the drug therapy advice
strong evidence supports pharmacotherapy for modifiable risk factors and antiplatelet therapy for secondary prevention